Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Force is with us: GEDI Chip Sorts Prostate Cancer Cells

Published: Friday, June 29, 2012
Last Updated: Friday, June 29, 2012
Bookmark and Share
Geometrically Enhanced Differential Immunocapture chip identify and collect cancer cells from a patient's bloodstream.

The future of prostate cancer therapy may lie in a tiny, "sticky" silicon chip dubbed GEDI (Geometrically Enhanced Differential Immunocapture, pronounced like the "Star Wars" forces of good) that can identify and collect cancer cells from a patient's bloodstream.

A team of researchers at Weill Cornell Medical College in New York City and Cornell's College of Engineering in Ithaca has built the chip into a device that captures an unprecedentedly high concentration of rare cancer cells from metastatic prostate cancer patients for a quick, noninvasive analysis to determine the efficacy of the patients' current chemotherapy.

The ability to collect a relatively pure sample of circulating tumor cells (CTCs) may also enable research to better understand the biology of metastasis and develop new treatments, the researchers said.

Their work is described in a paper in the April 2012 issue of the journal PLoS ONE, and was announced in a press conference at Weill by Brian Kirby, associate professor of mechanical and aerospace engineering; David Nanus, M.D., the Mark W. Pasmantier Professor of Hematology and Oncology in Medicine; and Evi Giannakakou, associate professor of pharmacology. The team includes 12 other researchers from both campuses.

Metastatic cancer is cancer that has spread from the place where it first started - in this case, the prostate - to another place in the body, most commonly the lungs, bones and liver. Metastasis accounts for the majority of cancer-related deaths.

"We need to be able to match the drug to the patient and the tumor," said Nanus. But tumor cells habitually mutate and develop a resistance to a previously effective therapy.

In the case of prostate cancer, three drugs are in common use, but the most effective one varies with the patient and the particular cancer.

Metastasis is believed to be caused by cells that detach from the primary prostate tumor, circulate in the bloodstream and seed new tumors.

Extensive clinical research shows that a reliable CTC count is a strong predictor of overall survival in metastatic prostate cancer patients.

However, since the incidence of CTCs can be very small - one CTC per 100 million blood cells - pure CTC capture is difficult.

"This really is a needle in a haystack," Kirby emphasized.

Cell-capture devices now in use contain antibodies that bind to an antigen found on the surface of nearly all malignant prostate cancer cells. But these antibodies also bind to other cells in the bloodstream and can collect a highly impure sample.

On the GEDI chip, a milliliter (mL, one-thousandth of a liter) of blood is pumped through a nanoscale channel filled with tiny posts just a few microns (millionths of a meter) in diameter, coated with antibodies.

Successive rows of posts are offset in a carefully calculated way so that only cells larger than 15 microns will collide with the posts and stick to them, while most smaller cells flow smoothly around them.

"Most cancer cells are bigger and more rigid than normal cells, so it's about tricking these cancer cells into colliding with the sticky walls," Kirby explained.

After the test the chip is removed from the device and the captured cells extracted for analysis. In an experiment with a blood sample containing 200mL of CTCs and 5 billion blood cells, the device captured a whopping 170mL of CTCs and only 91mL of irrelevant blood cells.

The GEDI device is scheduled to go into clinical trial this year. Meanwhile, the researchers are actively working on detectors for breast, ovarian and pancreatic cancers.

The research is one of several joint Ithaca-New York City projects associated with the Cornell Center for Microenvironment and Metastasis, a $13 million National Institutes of Health-funded Physical Sciences-Oncology Center created to use physical techniques and processes to improve understanding and care of metastatic cancer in patients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ingested Nanoparticles May Damage Liver
Although nanoparticles in food, sunscreen and other everyday products have many benefits, researchers from Cornell are finding that at certain doses, the particles might cause human organ damage.
Tuesday, August 12, 2014
Optical Traps on Chip Manipulate Many Molecules at Once
By shrinking the technology of an optical trap onto a single chip, Cornell physicists have created a device that can potentially reduce month-long experiments to days.
Wednesday, April 30, 2014
New Micro Water Sensor Can Aid Growers
Crop growers, wine grape and other fruit growers, food processors and even concrete makers all benefit from water sensors for accurate, steady and numerous moisture readings.
Monday, October 14, 2013
New DNA Cattle Test Beefs up Dairy and Meat Quality
A genomics technique developed at Cornell to improve corn can now be used to improve the quality of milk and meat.
Wednesday, May 22, 2013
NIH-Funded Tissue Chips would Predict Drug Safety
Researchers from Cornell University will develop microphysiological modules to model the nervous, circulatory and gastrointestinal tract systems.
Friday, August 31, 2012
Artificial Intestine Could Treat Children's Bowel Condition
A tiny 3-D collagen "scaffold" developed in a Cornell lab could prove a lifesaver for those who have lost parts of their intestine.
Monday, December 12, 2011
Microfluidic Devices for Circulating Tumor Cell Capture
The Kirby Research Group at Cornell University are attempting to use microfluidic devices to capture circulating tumor cells from prostate cancer patients, with a view towards preclinical evaluation of chemotherapeutic efficacy.
Tuesday, November 23, 2010
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
New Method to Preserve Device to Monitor HIV Treatment
Inspired by pregnancy tests, scientists have developed a method to store microfluidic devices for months without refrigeration, giving developing countries an inexpensive and reliable way to treat patients.
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!